ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Gilead taps Insitro to use machine learning to find new liver disease targets

by Ryan Cross
April 20, 2019 | APPEARED IN VOLUME 97, ISSUE 16

 

Gilead Sciences is forming a 3-year partnership with the machine-learning and genomics start-up Insitro to discover drug targets for nonalcoholic steatohepatitis. Insitro will earn $15 million up front and up to $35 million in near-term payments. The start-up could also get up to $200 million for each of five targets the duo pursues. Insitro also disclosed that it raised $100 million in its series A financing.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment